Drugs / SRX246
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02922166 | Feb 2017 → May 2019 | anxiety disorder | Azevan Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1 | NCT01088932 | Mar → Jun 2010 | — | Azevan Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00910455 | May → Sep 2009 | — | Azevan Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02055638 | May 2014 → May 2016 | intermittent explosive disorder | Azevan Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07328529 | Mar 2026 → Mar 2027 expected | fragile X syndrome | Azevan Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT02733614 | Dec 2016 → Oct 2020 | post-traumatic stress disorder | Azevan Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02507284 | May 2016 → Sep 2018 | Huntington disease, mood disorder | Azevan Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRX246 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02507284 ↗ |
| Action | Inhibit | “novel V1a vasopressin antagonist (SRX246)” NCT02055638 ↗1“Vasopressin V1a receptor antagonist” CHEMBL244243 ↗ |
| Modality | Small molecule | — CHEMBL244243 ↗ |
| Route | Oral | “orally administered SRX246” NCT00910455 ↗ |
| Target | AVPR1A | “Vasopressin V1a receptor antagonist” CHEMBL244243 ↗ |